STAAR Surgical Co
NASDAQ:STAA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
23.12
52.25
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
STAAR Surgical Co
STAAR Surgical Co
Cost of Revenue
STAAR Surgical Co
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
STAAR Surgical Co
NASDAQ:STAA
|
Cost of Revenue
-$72.6m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-11%
|
|
|
Haemonetics Corp
NYSE:HAE
|
Cost of Revenue
-$625.9m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-3%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Cost of Revenue
-$1.6B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-26%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Cost of Revenue
-$1.2B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-21%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Cost of Revenue
-$527.2m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-11%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Cost of Revenue
-$705m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-10%
|
|
STAAR Surgical Co
Glance View
In the early throes of medical innovation, STAAR Surgical Co. carved a niche within the ophthalmic industry, where its focus on implantable lenses set it apart from many contemporaries. Based in Monrovia, California, the company began its journey by enhancing an integral component of human life: vision. Through the skillful development and manufacture of implantable collamer lenses (ICLs), STAAR Surgical has thrived by providing solutions for those seeking alternatives to laser-based surgeries. Its ICL technology directly targets issues like myopia (nearsightedness) and astigmatism, offering patients a reversible, less invasive option than traditional corrective procedures. STAAR Surgical's business model hinges on a blend of specialized technology and strategic market penetration. The company primarily generates revenue by selling its suite of implantable lenses to healthcare providers and clinics worldwide, capitalizing on the rising trend of elective vision correction procedures. With its innovation-driven credo, STAAR continually invests in R&D to enhance its product offerings, ensuring it remains at the forefront of eye-care technology. By targeting emerging markets and expanding its global footprint, particularly in regions with growing demand for premium vision solutions, STAAR has positioned its unique value proposition to capitalize on both technological advancements and changing patient preferences. Through this deliberate strategy, STAAR not only bolsters its revenue streams but also fortifies its presence as a key player in the ophthalmic landscape.
See Also
What is STAAR Surgical Co's Cost of Revenue?
Cost of Revenue
-72.6m
USD
Based on the financial report for Sep 27, 2024, STAAR Surgical Co's Cost of Revenue amounts to -72.6m USD.
What is STAAR Surgical Co's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-11%
Over the last year, the Cost of Revenue growth was -6%. The average annual Cost of Revenue growth rates for STAAR Surgical Co have been -14% over the past three years , -15% over the past five years , and -11% over the past ten years .
You don't have any saved screeners yet